China Accepts Clinical Trial Application for SinoMab BioScience's Alzheimer's Treatment; Shares Rise 3%
China Accepts Clinical Trial Application for SinoMab BioScience's Alzheimer's Treatment; Shares Rise 3%
中國接受SinoMab BioScience阿爾茨海默氏症治療的臨床試驗申請；股價上漲3％
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊